Suptavumab: A Deep Dive into the REGN2222 Monoclonal Antibody REGN2222 is a therapeutic protein developed to selectively inhibit interleukin-18 , a important cytokine implicated in significant respiratory https://www.targetmol.com/compound/suptavumab